Relief Cardiovascular secured $12 million in Series A financing to advance its innovative Relief System for heart failure management.

Information on the Target

Relief Cardiovascular is an innovative medical device company based in Irvine, California, focused on revolutionizing the management of heart failure. The company has its flagship technology, the Relief System, which is a transcatheter smart implant aimed at enhancing fluid management for heart failure patients, thereby improving their quality of life. The Relief System employs a unique mechanism to monitor and modulate renal vein pressures, offering a new avenue for addressing fluid management challenges faced by patients.

Recently, Relief Cardiovascular successfully closed a $12 million Series A financing round to advance its first-in-human feasibility study for the Relief System. This financing was co-led by Broadview Ventures and Advent Life Sciences, with involvement from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategic partner. The raised funds will facilitate product development and the initiation of clinical studies to evaluate the safety and effectiveness of the technology.

Industry Overview in the Target’s Specific Country

The cardiac care sector in the United States is a rapidly evolving field, with rising incidences of heart disease and conditions such as heart failure driving innovation and investment. Heart failure, in particular, presents significant clinical challenges, char